Kyle Lefkoff - Net Worth and Insider Trading
Kyle Lefkoff Net Worth
The estimated net worth of Kyle Lefkoff is at least $5 Million dollars as of 2024-11-13. Kyle Lefkoff is the Director of Viridian Therapeutics Inc and owns about 138,061 shares of Viridian Therapeutics Inc (VRDN) stock worth over $3 Million. Kyle Lefkoff is also the Director of Array BioPharma Inc and owns about 37,720 shares of Array BioPharma Inc (ARRY) stock worth over $1 Million. Details can be seen in Kyle Lefkoff's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Kyle Lefkoff has not made any transactions after 2019-02-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Kyle Lefkoff
Kyle Lefkoff Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Kyle Lefkoff owns 2 companies in total, including Viridian Therapeutics Inc (VRDN) , and ARCA biopharma Inc (ABIO) .
Click here to see the complete history of Kyle Lefkoff’s form 4 insider trades.
Insider Ownership Summary of Kyle Lefkoff
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| VRDN | Viridian Therapeutics Inc | 2017-03-10 | director |
| ABIO | ARCA biopharma Inc | 2009-01-27 | 10 percent owner |
Kyle Lefkoff Latest Holdings Summary
Kyle Lefkoff currently owns a total of 2 stocks. Among these stocks, Kyle Lefkoff owns 138,061 shares of Viridian Therapeutics Inc (VRDN) as of March 10, 2017, with a value of $3 Million and a weighting of 67.83%. Kyle Lefkoff also owns 37,720 shares of Array BioPharma Inc (ARRY) as of February 6, 2019, with a value of $1 Million and a weighting of 32.17%.
Latest Holdings of Kyle Lefkoff
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| VRDN | Viridian Therapeutics Inc | 2017-03-10 | 138,061 | 22.44 | 3,098,089 |
| ARRY | Array BioPharma Inc | 2019-02-06 | 37,720 | 38.95 | 1,469,194 |
Holding Weightings of Kyle Lefkoff
Kyle Lefkoff Form 4 Trading Tracker
According to the SEC Form 4 filings, Kyle Lefkoff has made a total of 0 transactions in Viridian Therapeutics Inc (VRDN) over the past 5 years. The most-recent trade in Viridian Therapeutics Inc is the sale of 387 shares on March 10, 2017, which brought Kyle Lefkoff around $83,172.
According to the SEC Form 4 filings, Kyle Lefkoff has made a total of 0 transactions in Array BioPharma Inc (ARRY) over the past 5 years. The most-recent trade in Array BioPharma Inc is the sale of 35,000 shares on February 6, 2019, which brought Kyle Lefkoff around $721,000.
Insider Trading History of Kyle Lefkoff
- 1
Kyle Lefkoff Trading Performance
GuruFocus tracks the stock performance after each of Kyle Lefkoff's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kyle Lefkoff is 1.67%. GuruFocus also compares Kyle Lefkoff's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kyle Lefkoff within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Kyle Lefkoff's insider trading performs compared to the benchmark.
Performance of Kyle Lefkoff
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 5.67 | | | | | |
| Relative Return to S&P 500(%) | 6.57 | | | | | |
Kyle Lefkoff Ownership Network
Ownership Network List of Kyle Lefkoff
Ownership Network Relation of Kyle Lefkoff
Kyle Lefkoff Owned Company Details
What does Viridian Therapeutics Inc do?
Who are the key executives at Viridian Therapeutics Inc?
Kyle Lefkoff is the director of Viridian Therapeutics Inc. Other key executives at Viridian Therapeutics Inc include director & President and CEO Stephen F. Mahoney , Chief Operating Officer Thomas W. Beetham , and director & other: See Remarks Fairmount Healthcare Fund Ii Gp Llc .
Viridian Therapeutics Inc (VRDN) Insider Trades Summary
Over the past 18 months, Kyle Lefkoff made no insider transaction in Viridian Therapeutics Inc (VRDN). Other recent insider transactions involving Viridian Therapeutics Inc (VRDN) include a net sale of 9,796 shares made by Lara Meisner , a net purchase of 1,600,000 shares made by Fairmount Healthcare Fund Ii Gp Llc , and a net purchase of 476,190 shares made by Fairmount Healthcare Fund Gp Llc .
In summary, during the past 3 months, insiders sold 0 shares of Viridian Therapeutics Inc (VRDN) in total and bought 1,626,400 shares, with a net purchase of 1,626,400 shares. During the past 18 months, 9,796 shares of Viridian Therapeutics Inc (VRDN) were sold and 2,102,590 shares were bought by its insiders, resulting in a net purchase of 2,092,794 shares.
Viridian Therapeutics Inc (VRDN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Viridian Therapeutics Inc Insider Transactions
Kyle Lefkoff Mailing Address
Above is the net worth, insider trading, and ownership report for Kyle Lefkoff. You might contact Kyle Lefkoff via mailing address: 3200 Walnut St, Boulder Co 80301.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
